Matthew W. Foehr Sells 6,100 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) insider Matthew W. Foehr sold 6,100 shares of the stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $127.51, for a total value of $777,811.00. Following the transaction, the insider now directly owns 101,020 shares in the company, valued at approximately $12,881,060.20. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of Ligand Pharmaceuticals Incorporated (LGND) opened at 125.12 on Friday. The company has a market cap of $2.63 billion, a P/E ratio of 305.17 and a beta of 0.96. The company’s 50-day moving average price is $121.43 and its 200-day moving average price is $111.81. Ligand Pharmaceuticals Incorporated has a 12 month low of $87.50 and a 12 month high of $129.94.

Ligand Pharmaceuticals (NASDAQ:LGND) last released its earnings results on Monday, August 7th. The biotechnology company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.25 by $0.42. Ligand Pharmaceuticals had a return on equity of 5.05% and a net margin of 7.39%. The firm had revenue of $28 million during the quarter, compared to analysts’ expectations of $24.40 million. During the same period in the previous year, the firm posted $0.50 EPS. Ligand Pharmaceuticals’s revenue for the quarter was up 43.6% on a year-over-year basis. Equities analysts forecast that Ligand Pharmaceuticals Incorporated will post $2.95 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first published by Stock Observer and is the property of of Stock Observer. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.thestockobserver.com/2017/08/12/matthew-w-foehr-sells-6100-shares-of-ligand-pharmaceuticals-incorporated-nasdaqlgnd-stock.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. DUPONT CAPITAL MANAGEMENT Corp boosted its position in Ligand Pharmaceuticals by 46.6% in the first quarter. DUPONT CAPITAL MANAGEMENT Corp now owns 12,462 shares of the biotechnology company’s stock valued at $1,319,000 after buying an additional 3,960 shares during the last quarter. Granite Investment Partners LLC boosted its position in Ligand Pharmaceuticals by 25.4% in the first quarter. Granite Investment Partners LLC now owns 101,938 shares of the biotechnology company’s stock valued at $10,789,000 after buying an additional 20,622 shares during the last quarter. Court Place Advisors LLC boosted its position in Ligand Pharmaceuticals by 0.5% in the first quarter. Court Place Advisors LLC now owns 21,869 shares of the biotechnology company’s stock valued at $2,315,000 after buying an additional 100 shares during the last quarter. Independent Portfolio Consultants Inc. boosted its position in Ligand Pharmaceuticals by 1.0% in the first quarter. Independent Portfolio Consultants Inc. now owns 1,555 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 15 shares during the last quarter. Finally, State of Alaska Department of Revenue boosted its position in Ligand Pharmaceuticals by 1.9% in the first quarter. State of Alaska Department of Revenue now owns 2,100 shares of the biotechnology company’s stock valued at $222,000 after buying an additional 40 shares during the last quarter.

LGND has been the topic of a number of recent research reports. Zacks Investment Research downgraded Ligand Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, May 15th. BidaskClub raised Ligand Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. Roth Capital set a $120.00 price target on Ligand Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, May 22nd. TheStreet raised Ligand Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Monday, August 7th. Finally, Deutsche Bank AG reissued a “hold” rating and set a $103.00 price target (up previously from $100.00) on shares of Ligand Pharmaceuticals in a research report on Monday, July 17th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $133.71.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply